Expertise in
24
conditions

Dr. Tanya C. Watt

Hematology | Oncology
University Of Texas Southwestern Medical Center
5323 Harry Hines Blvd, 
Dallas, TX 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
24
conditions
University Of Texas Southwestern Medical Center
5323 Harry Hines Blvd, 
Dallas, TX 

Overview

Tanya Watt is a Hematologist and an Oncologist practicing medicine in Dallas, Texas.

Dr. Watt is highly rated in 24 conditions, according to our data. Her clinical expertise encompasses Neuroblastoma, Hereditary Neuroblastoma, Adrenal Cancer, and Acute Lymphoblastic Leukemia (ALL).

She is actively involved in clinical research, co-authoring 15 peer reviewed articles and participating in 18 clinical trials.

Specialties

Hematology
Oncology

Licenses

Pediatric Hematology-Oncology in TX

Languages Spoken

English
Spanish

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Baylor Scott & White Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
TeamCare
  • OTHER COMMERCIAL
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 4 Less Insurance Carriers -

Locations

University of Texas Southwestern Medical Center
5323 Harry Hines Blvd, Dallas, TX 75390

Additional Areas of Focus

Dr. Watt has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)
Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

18 Clinical Trials

A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 Alterations
A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 Alterations
Enrollment Status: Recruiting
Publish Date: September 04, 2026
Intervention Type: Drug
Study Drug: Oral Repotrectinib (TPX-0005)
Study Phase: Phase 1/Phase 2
Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2026
Intervention Type: Drug
Study Drug: Eflornithine
Study Phase: Phase 2
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Other
Study Drugs: Cabozantinib, Cabozantinib-S-Malate
Study Phase: Phase 2
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide
Study Phase: Phase 3
Neuroblastoma Biology Studies
Neuroblastoma Biology Studies
Enrollment Status: Completed
Publish Date: July 09, 2026
Intervention Type: Other
A Phase 1b/2 Study of Abemaciclib in Combination With Irinotecan and Temozolomide (Part A) and Abemaciclib in Combination With Temozolomide (Part B) in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors and Abemaciclib in Combination With Dinutuximab, GM-CSF, Irinotecan, and Temozolomide in Pediatric and Young Adult Patients With Relapsed/Refractory Neuroblastoma (Part C)
A Phase 1b/2 Study of Abemaciclib in Combination With Irinotecan and Temozolomide (Part A) and Abemaciclib in Combination With Temozolomide (Part B) in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors and Abemaciclib in Combination With Dinutuximab, GM-CSF, Irinotecan, and Temozolomide in Pediatric and Young Adult Patients With Relapsed/Refractory Neuroblastoma (Part C)
Enrollment Status: Completed
Publish Date: March 02, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Irinotecan, Temozolomide
Study Phase: Phase 1/Phase 2
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab With or Without Eflornithine (DFMO) in Children With Relapsed, Refractory or Progressive Neuroblastoma
A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab With or Without Eflornithine (DFMO) in Children With Relapsed, Refractory or Progressive Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: February 18, 2026
Intervention Type: Drug, Biological
Study Drugs: Dinutuximab, Eflornithine Hydrochloride, Irinotecan Hydrochloride, Sargramostim, Temozolomide
Study Phase: Phase 2
LEAHRN (Late Effects After High-Risk Neuroblastoma) Study
LEAHRN (Late Effects After High-Risk Neuroblastoma) Study
Enrollment Status: Active_not_recruiting
Publish Date: January 09, 2026
Intervention Type: Other
A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors
A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors
Enrollment Status: Active_not_recruiting
Publish Date: January 06, 2026
Intervention Type: Drug
Study Drug: Selpercatinib
Study Phase: Phase 1/Phase 2
Larotrectinib (LOXO-101, NSC# 788607) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias
Larotrectinib (LOXO-101, NSC# 788607) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias
Enrollment Status: Active_not_recruiting
Publish Date: December 02, 2025
Intervention Type: Drug
Study Drug: Larotrectinib Sulfate
Study Phase: Phase 2
View 9 Less Clinical Trials

15 Total Publications

A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric and Young Adult Solid Tumors.
A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric and Young Adult Solid Tumors.
Journal: Pediatric blood & cancer
Published: November 21, 2024
Similar Doctors
Expertise in
38
conditions
Dr. Farrukh T. Awan
Hematology | Oncology
Expertise in
38
conditions
Dr. Farrukh T. Awan
Hematology | Oncology
Referral may be required

UT Southwestern-Bill And Rita Clements Advanced Medical Imaging Center

2201 Inwood Rd, 
Dallas, TX 
 (0.6 miles away)
214-645-4673
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Farrukh Awan is a Hematologist and an Oncologist practicing medicine in Dallas, Texas. Dr. Awan is highly rated in 38 conditions, according to our data. His clinical expertise encompasses Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Small Lymphocytic Lymphoma (SLL), Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
33
conditions
Dr. Daniel C. Bowers
Hematology | Oncology
Expertise in
33
conditions
Dr. Daniel C. Bowers
Hematology | Oncology
Referral may be required

Children's Medical Center/Children's Health

1935 Medical District Dr, 
Dallas, TX 
 (0.2 miles away)
214-456-2382
Languages Spoken:
English
See accepted insurances

Daniel Bowers is a Hematologist and an Oncologist practicing medicine in Dallas, Texas. Dr. Bowers is highly rated in 33 conditions, according to our data. His clinical expertise encompasses Ependymoma, Posterior Fossa Tumor, Medulloblastoma, and Brain Tumor.

Expertise in
11
conditions
Dr. Naomi J. Winick
Hematology | Oncology
Expertise in
11
conditions
Dr. Naomi J. Winick
Hematology | Oncology
Referral may be required

Children's Medical Center/Children's Health

1935 Medical District Dr, 
Dallas, TX 
 (0.2 miles away)
214-648-3896
Languages Spoken:
English
See accepted insurances

Naomi Winick is a Hematologist and an Oncologist practicing medicine in Dallas, Texas. Dr. Winick is highly rated in 11 conditions, according to our data. Her clinical expertise encompasses Acute Lymphoblastic Leukemia (ALL), Leukemia, Febrile Neutropenia, Childhood Acute Myeloid Leukemia, and Bone Marrow Transplant.

Frequently Asked Questions about Dr. Tanya C. Watt

How do I make an appointment with Dr. Tanya C. Watt?

You can book an appointment with Dr. Tanya C. Watt by calling their office at 214-456-6363. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Tanya C. Watt a top-rated expert for Neuroblastoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Tanya C. Watt is classified as an Distinguished expert for Neuroblastoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Tanya C. Watt specialize in?

While Dr. Tanya C. Watt is a Hematology, they have specific expertise in Neuroblastoma, Hereditary Neuroblastoma, and Adrenal Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Tanya C. Watt participate in research or clinical trials?

Yes. Dr. Tanya C. Watt has published 15 articles and abstracts on conditions like Neuroblastoma. You can view a list of Dr. Tanya C. Watt's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Tanya C. Watt accept my insurance?

Dr. Tanya C. Watt accepts most major insurance plans, including Baylor Scott & White Health and Blue Cross Blue Shield. We recommend calling the office directly at 214-456-6363 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Watt's expertise for a condition
ConditionClose
    View All 23 Advanced Conditions
    View All 67 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile